ACKR4 Recruits GRK3 Prior to β-Arrestins but Can Scavenge Chemokines in the Absence of β-Arrestins

Christoph Matti¹, Angela Salnikov¹, Marc Artinger¹, Gianluca D’Agostino², Ilona Kindinger¹, Mariagrazia Uguccioni², Marcus Thelen² and Daniel F. Legler¹,³,⁴

¹ Biotechnology Institute Thurgau (BITg) at the University of Konstanz, Kreuzlingen, Switzerland, ² Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland, ³ Faculty of Biology, University of Konstanz, Konstanz, Germany, ⁴ Theodor Kocher Institute, University of Bern, Bern, Switzerland

Chemokines are essential for guiding cell migration. Atypical chemokine receptors (ACKRs) contribute to the cell migration process by binding, internalizing and degrading local chemokines, which enables the formation of confined gradients. ACKRs are heptahelical membrane spanning molecules structurally related to G-protein coupled receptors (GPCRs), but seem to be unable to signal through G-proteins upon ligand binding. ACKR4 internalizes the chemokines CCL19, CCL21, and CCL25 and is best known for shaping functional CCL21 gradients. Ligand binding to ACKR4 has been shown to recruit β-arrestins that has led to the assumption that chemokine scavenging relies on β-arrestin-mediated ACKR4 trafficking, a common internalization route taken by class A GPCRs. Here, we show that CCL19, CCL21, and CCL25 readily recruited β-arrestin1 and β-arrestin2 to human ACKR4, but found no evidence for β-arrestin-dependent or independent ACKR4-mediated activation of the kinases Erk1/2, Akt, or Src. However, we demonstrate that β-arrestins interacted with ACKR4 in the steady-state and contributed to the spontaneous trafficking of the receptor in the absence of chemokines. Deleting the C-terminus of ACKR4 not only interfered with the interaction of β-arrestins, but also with the uptake of fluorescently labeled cognate chemokines. We identify the GPCR kinase GRK3, and to a lesser extent GRK2, but not GRK4, GRK5, and GRK6, to be recruited to chemokine-stimulated ACKR4. We show that GRK3 recruitment preceded the recruitment of β-arrestins upon ACKR4 engagement and that GRK2/3 inhibition partially interfered with steady-state interaction and chemokine-driven recruitment of β-arrestins to ACKR4. Overexpressing β-arrestin2 accelerated the uptake of fluorescently labeled CCL19, indicating that β-arrestins contribute to the chemokine scavenging activity of ACKR4. By contrast, cells lacking β-arrestins were still capable to take up fluorescently labeled CCL19 demonstrating that β-arrestins are dispensable for chemokine scavenging by ACKR4.

Keywords: atypical chemokine receptor, ACKR4, CCL19, CCL21, CCL25, β-arrestin, GRK3
INTRODUCTION

Chemokines, a group of about 50 chemotactic cytokines, have fundamental roles in regulating immune responses, primarily by orchestrating leukocyte migration and controlling their localization (1, 2). The biological functions of chemokines are typically mediated by signaling through seven-transmembrane spanning, G-protein coupled receptors (GPCRs) (3, 4). The chemokines CCL19 and CCL21 are essential for guiding dendritic cells and subsets of T cells to lymph nodes by signaling through the cognate chemokine receptor CCR7 (5, 6) and thereby initiate adaptive immune responses. Notably, canonical CCR7 signaling by CCL19 and CCL21 is controlled by the G_{i} subfamily of G-proteins (7–9). In addition, chemokines bind to a small family of atypical chemokine receptors (ACKRs), which are structurally related to GPCRs but seem unable to elicit canonical, G-protein-dependent signal transduction pathways upon ligand binding (10, 11). However, ACKRs are emerging as crucial regulators for the availability of chemokines. Namely, ACKRs function as “decoy” or “scavenger” receptors that progressively internalize chemokines and sort them for lysosomal degradation to limit local and systemic chemokine concentrations (10, 12). The atypical chemokine receptor ACKR4, formerly also known as CCRL1 and CCX-CKR, is the scavenging receptor for CCL19, CCL21, and CCL25 (13–16). Notably, mice lacking ACKR4 systemically have a 5-fold increase in the level of CCL21 in the blood and a 2- to 3-fold increase in CCL19 and CCL21 in peripheral lymph nodes (17). Despite its expression on thymic epithelial cells where ACKR4 is supposed to scavenge the CCR7 and CCR9 ligands CCL19/CCL21 and CCL25, respectively, mice lacking ACKR4 seem to have a fairly normal thymic T cell lymphopoiesis (18). By contrast, ACKR4 expression by skin keratinocytes and a subset of dermal endothelial cells is critical for shaping functional CCL19/CCL21 gradients under steady-state and inflammatory conditions (17). These local CCL19/CCL21 gradients are essential for allowing dendritic cells to egress the skin and enter lymphatic vessels (19, 20). In addition, ACKR4 is present on lymphatic endothelial cells lining the ceiling of the subcapsular sinus, but not on those lining the floor, forming local CCL21 gradients in lymph nodes to guide dendritic cell homing in a CCR7-dependent manner (21). Consequently, the frequency of dendritic cells in the skin of ACKR4 deficient mice increases and dendritic cells fail to efficiently egress and migrate to draining lymph nodes (20, 21).

Although information on how ACKRs fulfill their scavenging function is limited, ACKR2-4 are known to spontaneously traffic between the plasma membrane and endosomes. Upon ligand binding, ACKRs internalize cognate chemokines and sort them for lysosomal degradation in a G-protein independent manner (10, 12, 16). The ability of ACKRs to scavenge chemokines has been linked to β-arrestins (22–26), which are universal intracellular adaptor proteins of GPCRs (27). In the case of classical GPCRs, β-arrestin recruitment depends on agonist-driven phosphorylation of serine/threonine residues situated at the receptor’s C-terminus by GPCR kinases (GRKs) or other protein kinases and leads to clathrin-mediated receptor endocytosis (28). This general concept has recently been challenged, at least for ACKRs, as chemokine uptake by ACKR2 (29), ACKR3 (30, 31), and ACKR4 (16) was observed in cells lacking β-arrestins. By contrast, ligand-mediated β-arrestin recruitment to ACKR4 (26), ACKR3 (24), and ACKR2 (29), as well as subsequent β-arrestin-dependent activation of Erk1/2 through ACKR3 (24) was reported. These controversial data prompted us to in depth investigate early signal transduction pathways and chemokine scavenging activities of ACKR4.

In the present study, we provide evidence that ACKR4 neither interacts with nor activates heterotrimeric G-proteins. Chemokine binding to ACKR4 does also not activate canonical chemokine receptor kinases, such as Erk1/2, Akt, or Src. By contrast, chemokine triggering recruited β-arrestin1 and β-arrestin2 to ACKR4. Moreover, we identify GRK3, and to a lesser extent GRK2, as interaction partner of chemokine engaged ACKR4 and show that GRK3 recruitment precedes the recruitment of β-arrestins upon receptor triggering. We further demonstrate that the C-terminus of ACKR4 is critical for spontaneous receptor trafficking, β-arrestin recruitment, and chemokine scavenging. Strikingly, overexpression of β-arrestins increased chemokine uptake by ACKR4, whereas in the absence of β-arrestins ACKR4 was still able to take up cognate chemokines although to a lesser extent, thus providing clear evidence that β-arrestins are dispensable for chemokine scavenging.

MATERIALS AND METHODS

Bioinformatics

Phosphorylation site and kinase interaction site predictions were performed using the native human ACKR4 sequence (uniport: Q9NPB9) and the webservers NetPhos Server 2.0 (http://www.cbs.dtu.dk/services/NetPhos/) (32), NetphosK 1.0 (www.cbs.dtu.dk/services/NetPhosK) (33), and the ELM resource (34). Secondary structure predictions were made using NetSurfP-2.0 (35) and human uniprot sequences (GNAI: P63096, GNAO: P09471, GNAQ: P50148, GNAS2: P63092, GNA13: Q14344).

Generation of Expression Plasmids

Reagents for molecular biology were purchased from Thermo Fisher Scientific and custom-designed primers from Microsynth. An overview of chemokine, receptor and β-arrestin constructs with corresponding primer sequences used for cloning are listed in Table 1. Briefly, pcDNA3 β-arrestin2i1-NLuc was generated by amplification of human β-arrestin2 and NLuc and subsequent ligation of the two PCR products over a common ClaI restriction site, followed by subcloning the DNA conjointly into the HindIII and XbaI sites of pcDNA3. Chemokines were amplified by PCR and further cloned into the XhoI and BsaI restriction sites of pET-HisSUMO (41). SUMO-hCCL19-S6 was amplified by PCR and cloned into the XhoI and XbaI restriction sites of pET-HisSUMO (41).

NLuc-GRK2 was generated by amplifying human GRK2 and NLuc separately, ligating the PCR products over a common ClaI restriction site and cloning it conjointly into the HindIII and XbaI sites of pcDNA3. The other GRK constructs were prepared...
**TABLE 1 |** General plasmids and primers.

| Construct | Template (if not synthesized); amplified insert in bold; [reference] | 5′-forward primer | 5′-reverse primer | Linker |
|-----------|-------------------------------------------------|------------------|-----------------|--------|
| pcDNA3 β-arrestin2i1-Nluc | pcDNA3 β-arrestin211-Y2 | GGTGGAAGACCTATAGGGGAGAAA CCG | GCATCGATCCACCGGAGAGTTGATC GGGTC | * |
| pAAVS1P-ICLHN Nluc | [Addgene plasmid # 66579](38) | - | - | - |
| pcDNA3 β-arrestin1A-Nluc | β-arrestin1A RC201279 (Origine) | GGTGGAAGACCTATAGGGGAGAAA CCG | GCATCGATCCACCGGAGAGTTGATC GGGTC | * |
| pEYFP β-arrestin2-EYFP | Published in (37) | GGACTCGAGAGCGGAGGTGGCGG TTCTGTTGAGACCTGCGCTGCGC CGGTCGTTAGCTAGTGAAAGAAGGC | GAATAGGAGGCCCTTACAGACTACTGTGA CAGCTGTCCATGC | ** |
| pcDNA3 HACKR4-EYFP | pcDNA3 CCR7-EYFP (9) | GGACTCGAGAGCGGAGGTGGCGG TTCTGTTGAGACCTGCGCTGCGC CGGTCGTTAGCTAGTGAAAGAAGGC | GAATAGGAGGCCCTTACAGACTACTGTGA CAGCTGTCCATGC | ** |
| pcDNA3 HACKR4t-EYFP | pcDNA3 hACKR4t-EYFP (38) | GGACTCGAGAGCGGAGGTGGCGG TTCTGTTGAGACCTGCGCTGCGC CGGTCGTTAGCTAGTGAAAGAAGGC | GAATAGGAGGCCCTTACAGACTACTGTGA CAGCTGTCCATGC | ** |
| pcDNA3 HACKR4-mTq2 | pcDNA3.1(−)Gaia1-mTurquoise2 (39) | GGACTCGAGAGCGGAGGTGGCGG TTCTGTTGAGACCTGCGCTGCGC CGGTCGTTAGCTAGTGAAAGAAGGC | GAATAGGAGGCCCTTACAGACTACTGTGA CAGCTGTCCATGC | ** |
| pcDNA3 HACKR4-HA | pcDNA3 ACKR4−EGFP (38) | GGACTCGAGAGCGGAGGTGGCGG TTCTGTTGAGACCTGCGCTGCGC CGGTCGTTAGCTAGTGAAAGAAGGC | GAATAGGAGGCCCTTACAGACTACTGTGA CAGCTGTCCATGC | ** |
| pcDNA3 hCCR7-EYFP | pcDNA3 CCR7-HA (40) | GGACTCGAGAGCGGAGGTGGCGG TTCTGTTGAGACCTGCGCTGCGC CGGTCGTTAGCTAGTGAAAGAAGGC | GAATAGGAGGCCCTTACAGACTACTGTGA CAGCTGTCCATGC | ** |
| pcDNA3 hCCR7-HA | Published in (40) | GGACTCGAGAGCGGAGGTGGCGG TTCTGTTGAGACCTGCGCTGCGC CGGTCGTTAGCTAGTGAAAGAAGGC | GAATAGGAGGCCCTTACAGACTACTGTGA CAGCTGTCCATGC | ** |
| pSUMO hCCL19 | pCR3-hCCL19−Fc (40) | GGACTCGAGAGCGGAGGTGGCGG TTCTGTTGAGACCTGCGCTGCGC CGGTCGTTAGCTAGTGAAAGAAGGC | GAATAGGAGGCCCTTACAGACTACTGTGA CAGCTGTCCATGC | ** |
| pSUMO hCCL21 | Published in (41) | GGACTCGAGAGCGGAGGTGGCGG TTCTGTTGAGACCTGCGCTGCGC CGGTCGTTAGCTAGTGAAAGAAGGC | GAATAGGAGGCCCTTACAGACTACTGTGA CAGCTGTCCATGC | ** |
| pSUMO hCCL25 | hCCL25 RC222128 (Origine) | GGACTCGAGAGCGGAGGTGGCGG TTCTGTTGAGACCTGCGCTGCGC CGGTCGTTAGCTAGTGAAAGAAGGC | GAATAGGAGGCCCTTACAGACTACTGTGA CAGCTGTCCATGC | ** |
| pSUMO hCCL19-S6 | pSUMO hCCL19 | GGACTCGAGAGCGGAGGTGGCGG TTCTGTTGAGACCTGCGCTGCGC CGGTCGTTAGCTAGTGAAAGAAGGC | GAATAGGAGGCCCTTACAGACTACTGTGA CAGCTGTCCATGC | ** |

**Linker sequence used between protein and tag.**

*GSI(GGGGS)*3.

**GGLES(GGGGS)*3.

***GARA.

****SGGGGS.

*****(GGGGS)*3GGS.

by replacing GRK2 with GRK3, GRK4, GRK5, and GRK6 using HindIII and Clai or Clai and XbaI, as listed in Table 2.

Site directed mutations of putative ACKR4 phosphorylation sites are listed in Table 3. Multiple site directed PCR were performed in consecutive cloning rounds to get ACKR4<sub>TT</sub>, ACKR4<sub>SSS</sub>, and ACKR4<sub>TTSSS</sub> mutants.

To generate the BRET constructs for G proteins, all redundant HindIII, Clai, BamHI, XhoI, or XbaI sites were removed by introducing silent mutations as listed in Table 4. Then, a BamHI site encoded in a SGGGGS linker was introduced (Table 5, Supplementary Figure 3). Further, the modified Ga<sub>α</sub>-subunits were amplified with adjacent HindIII and XbaI sites and cloned into pcDNA3. PCR amplified Nluc was introduced into the BamHI sites (Table 5). An exception is Ga<sub>α</sub><sub>q</sub>, were the RLuc8 in Ga<sub>α</sub><sub>q</sub>-RLuc8 was replaced via BamHI cutting and insertion of Nluc. To generate pRES Gβ−2A-cpV-Gγ2 Ga−Nluc, a redundant HindIII was removed and a new one added after the IRES sequence using site directed mutagenesis. Then the mutated IRES sequence was amplified using the forward primer hybridizing at a Sall site and the reverse primer with a HindIII site, hybridizing to the one introduced beforehand, followed by an XbaI site at its end. The PCR-product was ligated into the original IRES plasmid, removing the Ga<sub>α</sub>2-mTurquoise2 sequence, after digesting both with Sall and XbaI. Ga<sub>α</sub>1-Nluc was cut out from pcDNA3 Ga<sub>α</sub>1-Nluc utilizing HindIII and XbaI and ligated into the modified IRES vector.
TABLE 2 | GRK related plasmids and primers.

| Construct | Template (if not synthesized); amplified insert in bold; [reference] | 5'-forward primer | 5'-reverse primer | Linker |
|-----------|---------------------------------------------------------------------|-------------------|------------------|--------|
| pRK5-hGRK4 missing Xba site | pRK5-hGRK4 (addgene: #32690) (42) | GCTTTGCGATTGATCTCGAACAAAGA | GATGTA TGGCTTGTGGAGATCT TAA TGGCAAAAGC | |
| pRK5-hGRK4 missing HindIII and Xba site | pRK5-hGRK4 missing HindIII and Xba site | GTGAAATGGAAGGCTCCGCTCAT TGAACCTCG | GATAAGGC CGCTTCTGAGATCT CAGAAGG CCGCATGTCTG AGCCACCAGCAGCTT CAAAGCC GAGGAG | |
| pcDNA3 Nluc-GRK2 | pcDNA3 Nluc-GRK2 (addgene: #20418) | GTAGCGGTGGATCGATGGGGTCTTCAGA | GAGCTGGAAACATCGTG | |
| pcDNA3 GRK2-NLuc | pcDNA3 GRK2-NLuc | GAGACCCAAGCTTCATTACGATGGTG | GAGACCCAAGCTTCATTACGATGGTG | |
| pcDNA3 GRK3-NLuc | pcDNA3 GRK3-NLuc | GAGACCCAAGCTTCATTACGATGGTG | GAGACCCAAGCTTCATTACGATGGTG | |
| pcDNA3 GRK5-NLuc | pcDNA3 GRK5-NLuc | GAGACCCAAGCTTCATTACGATGGTG | GAGACCCAAGCTTCATTACGATGGTG | |
| pcDNA3 GRK6-NLuc | pcDNA3 GRK6-NLuc | GAGACCCAAGCTTCATTACGATGGTG | GAGACCCAAGCTTCATTACGATGGTG | |

Linker sequence used between protein and tag.
*GSI(GGGGS)3.
****(GGGGS)3GGS.

TABLE 3 | Phosphorylation site mutations in ACKR4-EYFP.

| Mutation | Nucleotide mutation | 5'-forward primer | 5'-reverse primer |
|----------|---------------------|-------------------|------------------|
| ACKR4Y68F | TA1103TT | GGTGGTTGCTCTATCTATGTTCAAAGAAGCAAAGA | CTTGGCTTCTGTGGAAGCATGATAGCAGAAACAA |
| ACKR4Y79F | TA1136TT | GACCGATG TCCTTCAATTTGGAACACTTGTTG | CAACCAAGGCCCATCAGAAATGACATCGG |
| ACKR4Y138F | TA1313TT | CATCTCTATTGATAGATTCGTTGCTGTTACCAAGC | CTAATCGGCAACCAGCCGAAGCAATCTATG |
| ACKR4T142A | A1325G | GATACGTTGCGATCTGCCAAGGTCCAAGG | CAAACACAGTTGGCTGGAACTGTGGA |
| ACKR4S146A | TCT1337GCC | GTTCATCAACAGGTCAAGG | CATCGTGGTACAGCAGGCAGG |
| ACKR4S148A | TCT1343GCC | CAAGCTGCACTCTAAAACAAGG | CATCGTGGTACAGCAGGCAGG |
| ACKR4T225A | ACT1577GCC | GCTACTTCATTACCGCTAGAGCCTTG | CTTGTTGCAACAGGAAGCATCAGAAATGACA |
| ACKR4S236A | T1607GCC | CATCCATCTATTACCGCTAGAGCCTTGAAAG | GATGTTGCAACAGGAAGCATCAGAAATGACA |
| ACKR4S323A | T1889G | GAGACCAAGCTTCATTACGATGGTG | GAGACCAAGCTTCATTACGATGGTG | |
| ACKR4S326A | T1889G | GAGACCAAGCTTCATTACGATGGTG | GAGACCAAGCTTCATTACGATGGTG | |

Chemokine Production
Recombinant human chemokines fused to a His6-SUMO-tag were purified from BL21 (DE3) E. coli and refolded by infinite dilution at pH 8.5. The His6-SUMO-tag was cleaved off by incubation with the Ulp-1 protease for 1–5 h and removed (41, 46, 47). Chemokines were purified by RP-HPLC on C18 columns.
To generate fluorescently tagged CCL19<sup>Dy649P1</sup>, human CCL19 fused to a His<sub>6</sub>-SUMO-tag and a SGGGGS-S6-tag was
expressed and purified as described above. CoA-conjugated (C3144-25MG, Sigma) Dy649P1 (Dy649P1-03, Dyomics GmbH) was prepared as described (46). Fluorescently labeled CCL19 Dy649P1 was generated by labeling purified CCL19-S6 with CoA-Dy649P1 at 37°C for 2 h using the phosphopantetheinyl transferase Sfp (P9302S, New England Biolabs) as previously described (46). Excess of substrate was removed from fluorescently labeled chemokine by reverse phase HPLC.

**Cell Culture and Transfection**

HeLa cells were cultured in DMEM (P04-04510, Pan Biotech), containing 1% penicillin/streptomycin (Pan Biotech), 10% FBS (Thermo Fisher Scientific). Cells were transfected at least 30 h prior to the experiments using the 100 µl Neon® Transfection System (Thermo Fisher Scientific) according to the manufacturer's protocol, transfecting 5 × 10⁵ cells with 10 µg total plasmid DNA. For BRET recruitment experiments, the DNA ratio of fluorophore to luciferase construct was 3:1, for Gαi activation experiments, the ratio of pcDNA3 receptor-HA to pIRES Gα-Nluc Gβγ-cpVenus construct was 1:3.

**Chemokine Mediated Erk1/2, Akt, and Src Activation**

HeLa cells were transfected either with pcDNA3 ACKR4-HA, pcDNA3 CCR7-HA or empty pcDNA3. After 36 h, cells were

---

**TABLE 4** Templates for Gα and site directed mutations thereof.

| Gα variant | Mutation effect | 5′-forward primer | 5′-reverse primer |
|------------|-----------------|-------------------|------------------|
| Gαi/13-RLuc8 | A kind gift from Nevin Lambert (44) | CGGAAGATGATTCCATGCTCGAGGAC | GTCTCGGCAATGGAATCCACTCTTCTGGC |
| Gαi | Synthesized | CATTGTCAGCAGATGAAGTCTGCTAGATGTTATGG | CCATTAACATGCAAGGTTCTCTATGCTCAG |
| Gαo | – BamHI site | GCCGCAGTTGAGCATCACCTGTTCAACG | GCCTCCAGCAGGAG |
| GαS | – BamHI site | CCCCGCGTAGTGAGCAGCTGACCTGGAC | CCACCTTGAACTGGGAGCTGCCAAGTACA |
| Gα13 | – BamHI site | CATATCCCTGTCAGGTCAGGATGAGGAGA | GAGATTTCCTTCATGAGATAATGGTCTCTCAGG |
| – HindIII site | CTCGAGAGAAGCTCCAGACAGGAG | GAAGATAGACTTGGTGACGTCAGCCCGAG |
| + BamHI site | GGAAGACCCAACATGCAAAAGAGATACGTTCTTCAGG | AGAGACCCAAGCTTCAGCCACCATGGGCTGCACGCTG |

**TABLE 5** Templates for Gα and Nluc amplification.

| Affected protein | Amplification of | 5′-forward primer | 5′-reverse primer |
|-----------------|------------------|-------------------|------------------|
| NLuc | BamHI-Nluc-BamHI | TCAGCTGGGGGATCCATGCTCGAGGAC | GATCGGCGATCCACCCAGGAGGCGCCGAGAAG |
| Gαi | HindIII-Gαi(1)-BamHI | GAGACCCAAGCTTCAGCCACCATGGGAGTACTCTGG | GATGTCGCTGCCAGGAG |
| + BamHI site | TCTGGCGGTGGAGGATCCGGCATCGAATATGGTGAT | CAGGGCCCTCTAGATCAAAAGCCGCGCCG |
| Gαi | HindIII-Gαi(2)-XbaI | TCTGTCGAGGAGGATGACTGCGCATCGAATATGGTGAT | GAGACCCAAGCTTCAGCCACCATGGGAGTACTCTGG |
| Gαo | HindIII-Gαo(1)-BamHI | GATACCCGACCTTCCACCCATGCAATATGGTGAT | GATGTCGCTGCCAGGAG |
| + BamHI site | TCTGTCGAGGAGGATGACTGCGCATCGAATATGGTGAT | GAGACCCAAGCTTCAGCCACCATGGGAGTACTCTGG |
| Gαi | HindIII-Gαi(2)-XbaI | GATACCCGACCTTCCACCCATGCAATATGGTGAT | GATGTCGCTGCCAGGAG |
| Gα13 | HindIII-Gα13-XbaI | GACCCCAAGCTTGGGAGCTTCCTCGCCGTC | GAGGCCCTCTAGATGATAAGGACACCACACAGTATTGATAGTTAG |
| GαS | HindIII-Gα2 -XbaI | GACCCCAAGCTTGGGAGCTTCCTCGCCGTC | GAGGCCCTCTAGATGATAAGGACACCACACAGTATTGATAGTTAG |

Cell Culture and Transfection

HeLa cells were cultured in DMEM (P04-04510, Pan Biotech), containing 1% penicillin/streptomycin (Pan Biotech), 10% FBS (Thermo Fisher Scientific). Cells were transfected at least 30 h prior to the experiments using the 100 µl Neon® Transfection System (Thermo Fisher Scientific) according to the manufacturer's protocol, transfecting 5 × 10⁵ cells with 10 µg total plasmid DNA. For BRET recruitment experiments, the DNA ratio of fluorophore to luciferase construct was 3:1, for Gαi activation experiments, the ratio of pcDNA3 receptor-HA to pIRES Gα-Nluc Gβγ-cpVenus construct was 1:3.
starved for 2 h with medium containing 0.5% serum before they were stimulated with 1 µg/ml (114 nM) human CCL19. Cells were lysed using NP-40 lysis buffer as described (9). Samples were separated by SDS-PAGE and phosphorylated (p) and total (t) amounts of signaling proteins detected by Western blotting using the following antibodies purchased from Cell Signaling Technology: tErk (#9102), pErk (#4370), tSrc (#2109), pSrc (#6943), tAkt (#9272), pAkt (#9271).

**BRET Measurements**

Transfected HeLa cells were grown in 6 well plates, washed with PBS, and detached using PBS based Gibco™ cell dissociation buffer (#13150104, Thermo Fisher Scientific) for a minimum of 3 min. Cells were collected in twice the volume of dissociation buffer with DMEM containing 10% FCS before being centrifuged for 2 min at 200 g. Cells were washed and resuspended in PBS containing 5% (w/v) glucose (PBS-G). Aliquots of around 8 × 10^6 cells in 40 µl were inoculated in white 96-flat-bottom half-well plates in the presence of 5 µM luciferase substrate coelenterazine H (C-7004, Biosynth) and stimulated with various concentrations of chemokines. Ratiometric BRET measurements were performed using a Tecan Spark™ 10M multimode microplate reader, measuring luciferase bioluminescence (384–440 nm, 350 ms integration time) and EYFP fluorescence (505–590 nm, 350 ms integration time) to calculate the BRET ratio between both signals (48). For short term observations (≤1 to 3 min), the integration time of both signals was decreased to 250 ms and an injector used for chemokine addition. To calculate NetBRET, BRET ratio of control wells containing luciferase and HA-tagged receptor instead of EYFP-tagged receptor was subtracted from the sample BRET ratio. For Gαi activation, the control wells contained cells transfected with pIRES Gαi-Nluc Ghγ-cpVenus alone. Area under the curve analysis (AUC) was performed using the measurements before stimulation as baseline and integrating the peak starting from 0 min until the end of measurement. For data representation of GRK and G protein activation, baseline reduction was performed using the measurements before addition of ligands, which is referred to as “corrected NetBRET.”

**Chemokine Uptake Assay**

Transfected HeLa cells were seeded at 4.5 × 10^4 cells per well in 24 well plates. Cells were washed with PBS and incubated for at least 10 min in 200 µl 50 mM HEPES-buffered, high glucose DMEM without phenol red (#21063045 Thermo Fisher Scientific) at 37 or 8°C, respectively. Fifty microliter of chemokine solution was added to the cells for indicated times. At t = 0 min, all cells were washed twice with PBS; acidic wash (100 mM NaCl, 50 mM glycine HCL, pH 3.0) was applied to the designated wells for about 45 s, followed by two PBS washes. Cells were detached by incubation with PBS based Gibco™ cell dissociation buffer and subsequently measured on a BD LSR II flow cytometer and FACSDiva™ software (BD Biosystems). Data were analyzed using the FlowJo™ 10.7 software.

**ACKR4 Receptor Staining and Chemokine Binding**

Transfected HeLa cells were seeded at 2.5 × 10^5 cells per well in 6 well plates. About 24–36 h post-transfection, cells were washed with FACS buffer (145 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 1 mM sodium phosphate, 5 mM HEPES, pH 7.5) and detached using Gibco Cell Dissociation Buffer (ThermoFisher). Cells were incubated with α-hACKR4 primary antibody (clone 13E11; #362102 Biolegend, dilution 1:750) at 8°C for 40 min followed by intense washing and incubation with goat α-mouse IgG coupled to Alexa647 (#A-21235 ThermoFisher, dilution 1:1000) for additional 20 min. To determine chemokine binding capacities to different ACKR4-EYFP mutants, transfected cells were incubated with 25 nM site specific labeled human CCL19 (CCL19DY649P1) at 8°C for 30 min. After washing, cells were analyzed by flow cytometry on a LSR II (BD Biosciences). Flow cytometry data were analyzed using FlowJo V10 (BD Biosciences). Medians of chemokine or antibody fluorescence of EYFP[+] cells were related to the median of EYFP to consider transfection efficiency.

**Confocal Fluorescence Microscopy**

Transfected HeLa were seeded in 6 well plates containing 18 mm 1.5H glass slides (#0117580 Marienfeld-Superior). After 36 h, cells were fixed using 4% formaldehyde and 1% glutaraldehyde and subsequently stained with phallodin-Alexa647 and mounted with DAPI Fluoromount-G (#0100-20, SouthernBiotech). A Leica TCS SP5 II confocal microscope with a 63x oil-immersion objective was used. Acquired images were processed using Fiji (49) and ImageJ2 (50). For deconvolution of 3D stacks, SVI Huygens Essential version 16.10.p3 was used.

**Data Analysis**

Data analysis and presentation was performed using GraphPad Prism V.7 and V8. For statistics with one variable, RM one-way ANOVA or mixed-effects analysis, both with Dunnett’s multiple comparisons test with a single pooled variance was performed (Figure 4). For statistics of Western blot ratio, mixed-effect model with Tukey’s multiple comparisons test with a single pooled variance was performed (Figure 1). For experiments using two variables, ordinary two-way ANOVA with Tukey’s multiple comparisons test, with individual variances computed for each comparison was performed (Figures 2, 5). EC50 values were calculated fitting a three parameter [agonist] vs. response curve. *p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.0001.

**RESULTS**

**ACKR4 Does Not Elicit Canonical Chemokine-Mediated Signal Transduction Pathways**

ACKRs, including ACKR4, were reported not to signal through heterotrimeric Gα-proteins manifested by the failure to induce cell migration or calcium mobilization (16, 26). However, it has been speculated that the Gα-protein might associate with ACKR4, hence sterically block Gα activation unless it
dissociates from the receptor (26). To address this possibility, we established bioluminescence resonance energy transfer (BRET)-based assays to measure G-protein activation and interaction with the receptor. We engineered human Gα-proteins (Gαi, Gαq, Gαs, Gαo, or Gα13) where we introduced the Nano luciferase (Nluc) as luminescence donor into the unstructured region of the receptor.

FIGURE 1 | ACKR4 does not interact with or activate G-proteins. (A) Schematic representation of BRET-based G-protein interaction, recruitment and dissociation assays. (B) HeLa cells were transiently transfected with either human CCR7-EYFP or human ACKR4-EYFP conjointly with Nluc fused to either Gαi, Gαq, Gαs, Gαo, or Gα13. NetBRET was determined before and after stimulating cells with 1 µg/ml (114 nM) human CCL19. n = 3. (C) Schematic representation of BRET-based G-protein activation assays. (D) HeLa cells expressing either human CCR7 or human ACKR4 together with an IRES vector coding for Gαi-Nluc and Gβγ-cpVenus were stimulated at t = 0 (indicated by an arrowhead) with 1 µg/ml CCL19 (solid lines) or PBS-G as control (dashed lines). G-protein activation was determined by measuring chemokine-mediated dissociation of the Gβγ- from the Gαi-subunit manifested by a decrease in NetBRET. Mean values and SEM of 3 independent experiments are shown. (E–G) Mock transfected (pcDNA3) and ACKR4-HA or CCR7-HA transfected HeLa cells were stimulated with 1 µg/ml CCL19 and total vs. phospho-Erk1/2 (E), total vs. phospho-Akt (F), and total vs. phospho-Src (G) was determined by Western blot densitometric analysis. Mean values and SEM of 4 independent experiments are shown.
FIGURE 2 | The C-terminus of ACKR4 is critical for β-arrestin recruitment and chemokine uptake. (A) Schematic representation of BRET-based β-arrestin recruitment assay. HeLa cells co-transfected with ACKR4-EYFP and β-arrestin1-Nluc (B) or β-arrestin2-Nluc (C) were stimulated with graded concentrations of either human CCL19, CCL21, or CCL25 and β-arrestin recruitment to ACKR4 determined by BRET. n = 4. (D) HeLa cells co-transfected with β-arrestin2-Nluc together with ACKR4-EYFP or tailless ACKR4t-EYFP and stimulated at t = 0 min (indicated by an arrowhead) with 1.5 µM CCL19 and mean NetBRET and SEM derived from four (Continued)
after the second helix (51). As luminescence-acceptor, we used human ACKR4, or human CCR7, fused to EYFP to measure steady-state association, chemokine-driven recruitment, as well as activation-dependent dissociation of the heterotrimeric G-protein from the receptor (Figure 1A). Co-expressing Ga-NLuc variants together with ACKR4-EYFP in HeLa cells revealed that none of these tested Ga-proteins associated with ACKR4 under steady-state conditions (Figure 1B). Stimulating cells with 1μg/ml of human chemokine CCL19, known to elicit strong CCR7 responses, neither recruited one of the Ga-proteins to ACKR4, nor in the dissociation of one of the G-proteins from the receptor (Figure 1B). By contrast, Gaαi was found to pre-associate with the canonical chemokine receptor CCR7-EYFP and dissociated from the receptor upon CCL19 stimulation (Figure 1B), which is in line with the pre-association of the Gaαi-protein with the adrenergic receptor and its subsequent ligand-induced dissociation (51). Next, we used Gaαi-NLuc and Gβγi fused to cPvenus as luminescence-acceptor to monitor activation-induced dissociation of Gβγi from the Gaαi-subunit (Figure 1C). Whereas, CCL19 stimulation led to the dissociation of the Gaαi from the Gβγi-subunit upon CCR7 triggering, this was not observed for ACKR4 (Figure 1D). Consistent with these findings, CCL19 triggering of CCR7, but not of ACKR4, lead to the phosphorylation and activation of the MAP kinase Erk1/2 (Figure 1E, Supplementary Figure 1) and protein kinase B/Akt (Figure 1F, Supplementary Figure 1) through the canonical Gaαi-signaling pathway (7–9). Moreover, CCL19 stimulation of CCR7 caused the phosphorylation of the kinase Src (Figure 1G, Supplementary Figure 1), which occurs through G-protein-independent signaling (9). Again, no CCL19-mediated Src phosphorylation was observed upon ACKR4 triggering (Figure 1G, Supplementary Figure 1). These data provide comprehensive evidence that ACKR4 does neither associate with and activate G-proteins, nor elicits canonical chemokine receptor signaling pathways involving Erk1/2, Akt or Src kinases.

The C-Terminus of ACKR4 Controls Interaction and Recruitment of β-Arrestins and Is Essential for Chemokine Uptake

As the role of β-arrestins in chemokine scavenging by ACKR4 is debated (16, 26), we determined β-arrestin1 and β-arrestin2 recruitment to ACKR4 by BRET (Figure 2A). We co-expressed EYFP-tagged human ACKR4 together with either Nluc-tagged human β-arrestin1 or β-arrestin2 in Hela cells and stimulated the cells with graded concentrations of the human ACKR4 ligands CCL19, CCL21, and CCL25. All three chemokines recruited β-arrestin1 (Figure 2B) and β-arrestin2 (Figure 2C) to ACKR4. CCL19 was the most potent agonist in recruiting β-arrestin1 (EC50~76 nM) and β-arrestin2 (EC50~32 nM). EC50 values for CCL21 were ~240 nM (β-arrestin1) and ~133 nM (β-arrestin2), those for CCL25 ~115 nM and ~130 nM, respectively (Figures 2B, C). As β-arrestin recruitment to a GPCR is controlled by phosphorylation of serine/threonine residues located at the receptor’s C-terminus, we generated a tailless human ACKR4 variant by truncating the receptor directly after the conserved NPxxY motif (ACKR4t~3041; termed ACKR4t). As expected, ACKR4t failed to recruit β-arrestin1 or β-arrestin2 upon chemokine stimulation (Figure 2D, Supplementary Figure 2). Notably, ACKR4t already showed a markedly reduced steady-state interaction with β-arrestins before the chemokine was added compared to wild-type ACKR4 (Figure 2D). To confirm and visualize β-arrestin interaction with ACKR4 under steady-state conditions, we exploited a split-YFP based biomolecular fluorescence complementation (BiFC) assay (9, 48, 52). We found that BiFC between ACKR4-splitYFP2 and β-arrestin2-splitYFP1 was predominantly found in vesicular structures (Figure 2E), suggesting that β-arrestins might contribute to the steady-state trafficking of ACKR4. Consistent with this hypothesis, ACKR4t (fused to EYFP) was predominantly expressed at the plasma membrane (Figure 2F). To assess chemokine scavenging, we incubated HeLa cells expressing either ACKR4-EYFP or ACKR4t-EYFP with fluorescently labeled CCL19 (CCL19DY649P1) at either 8°C (to measure chemokine binding) or 37°C (to determine chemokine uptake; Figure 2G). At 8°C, both ACKR4 variants bound CCL19DY649P1 with ACKR4t being slightly, but not significantly, more efficient (Figure 2H). Surface bound CCL19DY649P1 was effectively removed by a short acidic wash (Figure 2H). Incubating ACKR4-EYFP expressing cells at 37°C resulted in a marked uptake of CCL19DY649P1 which resisted the acidic wash, indicating that the chemokine was indeed rapidly internalized (Figure 2H). By contrast, using the same conditions, CCL19DY649P1 bound to ACKR4t-EYFP, but was efficiently removed by an acid wash (Figure 2H), revealing that ACKR4b lacking its C-terminus fail to efficiently take up CCL19.

Chemokine Triggering Recruits GRK3, and to a Lesser Extent GRK2, to ACKR4

To identify which GRK promotes putative receptor phosphorylation and subsequent β-arrestin recruitment we established BRET assays to measure recruitment of individual GRKs to engaged ACKR4 (Figure 3A). Therefore, we fused Nluc to all ubiquitously expressed human GRKs and co-expressed them individually with ACKR4-EYFP in HeLa
FIGURE 3 | Chemokine stimulation selectively recruits GRK3 and GRK2 to ACKR4. (A) Scheme of chemokine-mediated GRK recruitment determined by BRET. (B) HeLa cells were co-transfected with ACKR4-EYFP and GRK5-NLuc or β-arrestin2-NLuc and stimulated with CCL19. Chemokine-mediated GRK5 or β-arrestin2 recruitment was determined by NetBRET (left). NetBRET values before chemokine stimulation (baseline) was subtracted for corrected NetBRET values (middle). Corrected NetBRET values over time after chemokine addition was integrated and depicted as area under the curve (AUC) values (right). Chemokine addition is

(Continued)
cells. As internal control we also determined β-arrestin2-Nluc recruitment to ACKR4-EYFP. Cells were stimulated with the three ACKR4 ligands at a concentration representing about 3·times the EC50 value of β-arrestin2 recruitment. To determine chemokine-mediated recruitment of signaling molecules, basal NetBRET values were subtracted for each condition and the area under the curve (AUC) for the first 3 min of stimulation were calculated as depicted in Figure 3B. A comprehensive analysis revealed that CCL19, CCL21, and CCL25 showed similar EC50 values for the recruitment of GRK3-Nluc (Figure 3D) revealed EC50 values for the recruitment of GRK3 to ACKR4, whereas no interaction of ACKR4 with GRK4, GRK5, or GRK6 was observed (Figure 3C). Dose-response kinetic analysis revealed similar EC50 values for the recruitment of GRK3 (Figure 3D) by CCL19 (EC50∼42 nM), CCL21 (EC50∼142 nM), and CCL25 (EC50∼147 nM), as determined for the recruitment of β-arrestin2 by these ACKR4 agonists. Chemokine-mediated GRK3 recruitment to ACKR4 was fast, reaching its maximum within a minute (Figure 3E), and preceded the recruitment of β-arrestin1 and β-arrestin2 (Figure 3F). A less pronounced chemokine-mediated BRET signal was also observed between GRK2 and ACKR4 (Figures 3C,H). Subsequent dose-response kinetic analysis for GRK2 (Figure 3G) revealed EC50 values for CCL19 (EC50∼35 nM), CCL21 (EC50∼129 nM), and CCL25 (EC50∼87 nM) that are comparable to those for GRK3. The chemokine-mediated interaction between GRK2/3 and ACKR4 was not as transient as one could expect, which can be explained by the spontaneous trafficking of ACKR4 that continuously deliver receptor molecules to the plasma membrane that can interact with GRK2/3 over time and upon chemokine triggering. Notably, steady-state interaction of GRK2/3 with the tailless variant ACKR4 was abrogated and no chemokine-mediated recruitment of GRK2 or GRK3 to ACKR4 was observed (Figure 3I). To investigate the role of GRK2/3 in the recruitment of β-arrestin to ACKR4, we treated cells with cmpd101, a known GRK2/3 inhibitor (31). Treating cells with cmpd101 reduced both basal interaction of ACKR4 with β-arrestin2 (Figure 3J), as well as chemokine-mediated β-arrestin2 recruitment to the receptor (Figures 3K,L).

Notably, although cmpd101 treatment interfered with the recruitment of β-arrestin to ACKR4, the interaction was not completely abolished, suggesting that other kinase(s) contribute to potential ACKR4 phosphorylation and subsequent β-arrestin recruitment. To address this, we searched for putative serine/threonine phosphorylation sites of ACKR4. In silico studies using NetPhos 2.0 server (http://www.cbs.dtu.dk/services/NetPhos/) and NetPhosK 1.0 server (www.cbs.dtu.dk/services/NetPhosK) predicted several putative phosphorylation sites or protein binding motifs for ACKR4 (Figure 4A). In order to validate these putative phosphorylation and kinase binding sites of ACKR4, we performed site-directed mutagenesis to exchange tyrosine residues for phenylalanine and serine/threonine residues for alanine and determined steady-state interaction and CCL19-driven recruitment of β-arrestin2 by BRET as depicted in Figure 4B. Whereas none of the tyrosine mutants affected steady-state interaction or stimulation-dependent recruitment of β-arrestin2 to ACKR4, a number of serine/threonine single point-mutants significantly reduced the interaction between β-arrestin2 and ACKR4 (Figure 4C). Most prominently, ACKR4T142A showed severely impaired steady-state interaction with β-arrestin2 without affecting the chemokine-driven β-arrestin2 recruitment. Importantly, none of these ACKR4 mutants showed significantly impaired surface expression or CCL19-mediated binding capabilities (Figure 4D). Additional sites affecting the steady-state interaction with β-arrestin2 include ACKR4S330A, ACKR4S323A, and ACKR4S330A, which, together with ACKR4T142A, are predicted as putative PKC phosphorylation sites (Figures 4A,C). Thus, we generated additional mutants, where the two threonine residues (ACKR4S323S330) of the combination thereof (ACKR4TTSSmut) were replaced by alanines. Notably, steady-state interaction of ACKR4TTSSmut with β-arrestin2 was profoundly reduced, whereas the other two mutants showed an intermediate phenotype (Figure 4E). Similarly, ACKR4TTSSmut showed a significantly decreased ability to recruit β-arrestin2 upon CCL19 stimulation (Figure 4E), while retaining their surface expression and chemokine binding abilities (Figure 4F).

Taken together, these data demonstrate that chemokine triggering selectively recruits GRK3, and to a lesser extent GRK2, to ACKR4 and suggest that GRK2/3 and other serine/threonine kinases contribute to the recruitment of β-arrestins to the receptor. Although, mutating selected serine and threonine residues is not a direct proof that these residues are indeed phosphorylated by GRK2/3, our data provide evidence that these residues are critical for β-arrestin recruitment.

**β-Arrestins Contribute to, but Are Disposable for Chemokine Uptake**

To assess the role of β-arrestins in steady-state trafficking and chemokine scavenging by ACKR4, we exploited wild-type HeLa (HeLa wt) and β-arrestin1/β-arrestin2-double deficient HeLa (HeLa KO) cells expressing mTurquoise2-tagged ACKR4.
Matti et al.

β-Arrestins Modulate Chemokine Scavenging

FIGURE 4 | Site-specific mutation analysis of ACKR4 for putative kinase interaction sites. (A) Schematic representation of ACKR4. In silico predicted phosphorylation sites are highlighted in red and putative kinase for site-specific tyrosine or serine/threonine phosphorylation are depicted. Numbers indicate individual mutant clones analyzed in (C). (B) HeLa cells were transfected with ACKR4-EYFP and β-arrestin2-Nluc and stimulated with 1 µg/ml (114 nM) CCL19 and steady-state interaction before chemokine stimulation and chemokine-mediated recruitment determined by NetBRET of a representative experiment out of four is shown. (C,E) HeLa cells were transfected with mutants of ACKR4-EYFP together with β-arrestin2-Nluc and steady-state interaction (C) as well as CCL19-mediated β-arrestin2 recruitment was determined as outlined in (B). (D,F) HeLa cells were transfected with mutants of ACKR4-EYFP and surface expression using antibody staining or chemokine binding (25 nM CCL19Dy649P1 at 8°C) was determined by flow cytometry. n = 3–5.

ACKR4-mTq2. ACKR4-mTq2 showed the expected surface and mainly vesicular localization in HeLa wt cells (Figure 5A). By contrast, ACKR4-mTq2 predominantly associated with the plasma membrane in HeLa KO cells and was less present in vesicular structures (Figure 5A), similarly to ACKR4t-EYFP (Figure 2F). Reconstituting HeLa KO cells by
FIGURE 5 | β-arrestins contribute to, but are dispensable for CCL19 uptake. (A) Wild-type (wt) HeLa cells or β-arrestin1 and β-arrestin2 double gene targeted HeLa cells (KO) were co-transfected with ACKR4-mTq2 and β-arrestin2-YFP or empty vector, fixed, stained with phalloidin Alexa647 and analyzed by confocal microscopy. Cell shapes are marked with a dashed line (outer-left panels). Scale bar = 25 µm or 2.5 µm for zoomed images. (B) Scheme of CCL19 Dy649P1 binding to mTq2-tagged ACKR4. (C) HeLa cells (ut, dashed line) were transfected with ACKR4-mTq2 (blue line) and incubated for 0 (t = 0) or 60 min (t = 60) at 37 °C with 5 nM fluorescently labeled CCL19 Dy649P1. ACKR4-mTq2 expression and chemokine uptake (by receptor + cells) was determined by flow cytometry. One representative experiment including gating strategy is shown. (D,E) HeLa wt or HeLa KO cells over-expressing or not β-arrestin2 were transfected with ACKR4-mTq2 and incubated with 5 nM CCL19 Dy649P1 for indicated times and chemokine uptake determined by flow cytometry. Mean values and SEM (D) or SD (E) are shown. Cumulative chemokine uptake over time, as determined by the area under the curve (AUC) of the experiments shown in (D). Where indicated, cells were exposed to a short acidic wash to remove surface bound, but not internalized CCL19 Dy649P1. n = 4.

reintroducing β-arrestin2-YFP, promoted the re-localization to predominantly vesicular and surface localization of ACKR4-mTq2 (Figure 5A), supporting the notion that β-arrestins control the steady-state trafficking of ACKR4. To asses ACKR4-mediated chemokine scavenging, we incubated transfected HeLa cells with fluorescently labeled CCL19 Dy649P1 for various time points at 37°C (Figures 5B,C). CCL19 Dy649P1 was steadily taken up over time by ACKR4 in HeLa wt cells (Figure 5D). Exposing cells to a short acidic wash hardly reduced chemokine-derived fluorescence, indicated that CCL19 Dy649P1 was indeed internalized (Figure 5E). Remarkably, uptake of CCL19 Dy649P1 was significantly reduced by roughly ~40–50% in HeLa KO cells, but was not completely abolished (Figures 5D,E). Moreover, overexpression of β-arrestin2 in either HeLa wt or HeLa KO cells significantly enhanced CCL19 Dy649P1 uptake (Figures 5D,E).

In summary, we show that β-arrestins interact with ACKR4 in the steady-state and contribute to the spontaneous trafficking
of the receptor. Furthermore, we demonstrate that β-arrestins enhance the scavenging activity of ACKR4, but are dispensable for chemokine uptake.

**DISCUSSION**

ACKR4 plays an important role in the regulation of immune cell migration by shaping local chemokine gradients (20, 21). The molecular mechanism how ACKR4 scavenges its cognate ligands remains poorly understood. Initially, biotinylated CCL19 was detected in vesicular structures of ACKR4 transfected MEFs derived from β-arrestin1/β-arrestin2 double-deficient mice, suggesting that chemokine uptake by ACKR4 is not critically dependent on β-arrestins (16). By contrast, CCL19 stimulation of an ACKR4 transfected osteosarcoma cell line was shown to result in the translocation of β-arrestin2-GFP to vesicular structures (26). In addition, chemokine stimulation recruited β-arrestin1 and β-arrestin2 to ACKR4 using slit-galactosidase and BRET assays in CHO cell transfectants (26). This later study is in line with the common concept of a β-arrestin-dependent receptor trafficking route taken by class A GPCRs (27). In the present study we show that CCL19, CCL21, and CCL25 effectively recruit β-arrestin1 and β-arrestin2 to engaged ACKR4, which confirms the study by Watts and colleagues (26). In addition to that study, we found that β-arrestin already interacts with ACKR4 prior to chemokine stimulation and that this steady-state interaction occurs at vesicular structures. Notably, an ACKR4 mutant lacking its C-terminus not only failed to interact with and recruit β-arrestins, it also lost its vesicular localization and showed an impaired capacity to take up chemokines. Interestingly, a C-terminally truncated variant of ACKR2 also fails to recruit β-arrestins, but was still able to scavenge chemokines (29), whereas a C-terminal deletion variant of ACKR3 (31, 53) showed a similar absence of chemokine scavenging behavior as ACKR4. Together with the finding that overexpression of β-arrestin2 enhanced chemokine uptake, our data indicate that β-arrestins control steady-state trafficking of ACKR4 and contributes to an enhanced chemokine scavenging activity. However, we also provide experimental evidence that β-arrestins are dispensable for chemokine uptake by ACKR4, as β-arrestin1/β-arrestin2-double deficient HeLa cells are still able to internalize chemokines although less efficient that wild-type cells. Notably, CCL19 uptake by ACKR4 was shown to be partially reduced in HEK293 cells treated with methyl-β-cyclodextrin to deplete cholesterol or in cells overexpressing caveolin-1 or a dominant-negative form of dynamin, but not in cells overexpressing a dominant-negative form of Eps15 or Rab5 (16). These data conjointly suggest, that ACKR4 and likely other ACKRs utilize additional routes of endocytosis compared with canonical chemokine receptors.

Due to the lack of canonical G protein-dependent signaling, ACKRs were initially considered to be silent receptors. More recently, ACKR3 was described to execute a signaling bias toward β-arrestins leading to MAP kinase activation (24), an alternative signaling pathway for canonical class A GPCRs (27). β-arrestin signaling usually relies on GPCR kinase recruitment and subsequent receptor phosphorylation. Consistent with this concept, GRK2 (and partially GRK5) recruitment was shown to induce ACKR3 phosphorylation upon chemokine stimulation (31). Here, we identified that GRK3 and GRK2, but no other GRK, are selectively recruited to chemokine engaged ACKR4 and that GRK2/3 recruitment precedes the recruitment of β-arrestins, pointing to a remarkable specificity of GRKs for different ACKRs. Inhibiting GRK2/3 by cpmd101 partially, but significantly reduced steady-state interaction as well as chemokine-driven recruitment of β-arrestins to ACKR4. However, we did not find any experimental evidence for a β-arrestin-dependent or independent phosphorylation of Erk1/2 and Akt upon chemokine triggering of ACKR4. Our data are thus in line with a previous study on ACKR4 showing no Erk1/2 activation (26) and one on the adrenergic receptor showing that β-arrestins are dispensable for Erk1/2 phosphorylation (54).

In conclusion, it emerges that distinct GRKs are recruited to ACKRs (GRK2/5 for ACKR3; GRK2/3 for ACKR4) upon ligand stimulation, which phosphorylate C-terminal serine/threonine residues of the receptor (31) and thereby recruit β-arrestins. We herein further provide evidence that β-arrestins control steady-state trafficking of ACKR4 and promote chemokine uptake. However, it is becoming clear that β-arrestins are dispensable for chemokine scavenging by ACKR2 (29), ACKR3 (30, 31) and ACKR4 (16). The fact that GRKs are recruited to and phosphorylate the receptors strongly indicates that ACKRs are not silent receptors, but are able to elicit alternative, yet unknown signaling pathways. This is most convincingly supported by the fact that mice lacking ACKR3 die at birth with ventricular septal defects and semilunar heart valve malformation (55), while mice expressing a chemokine scavenging deficient ACKR3 are vital (31).

**DATA AVAILABILITY STATEMENT**

Datasets for this study are deposited on Zenodo and are publicly available under a Creative Commons Attribution 4.0 International license, doi: 10.5281/zenodo.3631895.

**AUTHOR CONTRIBUTIONS**

CM and DL designed the studies and wrote the manuscript. CM, AS, MA, and IK performed the experiments. GD’A and MU contributed HeLa KO cells. CM, AS, MA, MT, and DL analyzed the data. DL supervised the overall study.

**ACKNOWLEDGMENTS**

This work was supported by the Swiss National Science Foundation [Sinergia CRSII3_160719 (to MT and DL)], the Helmut Horten Foundation (MU and MT), the Konstanz Research School Chemical Biology (KoRSc-Bio), the Crescere Stiftung Thurgau, the Thurgauische Stiftung für Wissenschaft und Forschung, and the State Secretariat for Education, Research and Innovation (DL).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2020.00720/full#supplementary-material
REFERENCES

1. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. *Ann Rev Immunol.* (2014) 32:659–88. doi: 10.1146/annurev-immunol-032713-120145

2. Legler DF, Thelen M. Chemokines: chemistry, biochemistry and biological function. *Chimia.* (2016) 70:856–9. doi: 10.2533/chimia.2016.856

3. Thelen M, Stein JV. How chemokines invite leukocytes to dance. *Nat Immunol.* (2008) 9:953–9. doi: 10.1038/ni.2007

4. Legler DF, Thelen M. New insights in chemokine signaling, F1000Res. (2018) 7:95. doi: 10.12688/f1000research.13130.1

5. Forster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. *Nat Rev Immunol.* (2008) 8:362–71. doi: 10.1038/nri2299

6. Hauser MA, Legler DF. Common and biased signaling pathways of the chemokine receptor CCR7 elicited by its ligands CCL19 and CCL21 in leukocytes. *J Leukoc Biol.* (2016) 99:869–82. doi: 10.1189/jlb.2MR0813-380R

7. Otero C, Eisele PS, Schaebbe K, Grootetrup M, Legler DF. Distinct motifs in the chemokine receptor CCR7 regulate signal transduction, receptor trafficking and chemotaxis. *J Cell Sci.* (2008) 121:2759–67. doi: 10.1242/jcs.029074

8. Schaebbe K, Hauser MA, Singer E, Grootetrup M, Legler DF. Cross-talk between TCR and CCR7 signaling sets a temporal threshold for enhanced T lymphocyte migration. *J Immunol.* (2011) 187:5645–52. doi: 10.4049/jimmunol.1100188

9. Hauser MA, Schaebbe K,Kindinger I, Impellizzieri D, Krueger WA, Hauck CR, et al. Inflammation-induced CCR7 oligomers form scaffolds to integrate distinct signaling pathways for efficient cell migration. *Immunology.* (2016) 44:59–72. doi: 10.1016/j.immu.2015.12.010

10. Nibbs RJ, Graham GJ. Immune regulation by atypical chemokine receptors. *Nat Rev Immunol.* doi: 10.1016/S0378-1119(00)00076-7

11. Bacherelier F, Ben-Baruch A, Burkhardt AM, Combedi C, Farber JM, Graham GJ, et al. International Union of Pharmacology. LXXIX: update on the extended family of chemokines and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. (2014) 66:1–79. doi: 10.1124/pr.113.007724

12. Ulvmar MH, Hub E, Rot A. Atypical chemokine receptors. Exp Cell Res. (2011) 317:556–68. doi: 10.1016/j.yexcr.2011.01.012

13. Kosigg J, Dairagh DJ, Wang Y, Hanley M, Talbot J, Brown T, Shyamala V, et al. Cutting edge: identification of a novel chemokine receptor that binds dendritic cell- and T cell-active chemokines including ELC, SLC, and TECK. *J Immunol.* (2000) 164:2851–6. doi: 10.4049/jimmunol.164.6.2851

14. Khoja H, Wang G, Ng CT, Tucker J, Brown T, Shyamala V, et al. Cloning of human chemokine decoy receptor D6. *J Biol Chem.* (2000) 275:25590–7. doi: 10.1074/jbc.M400363200

15. Lucas B, White AJ, Ulvmar MH, Nibbs RJ, Sitnik KM, Agace WW, et al. ACKR4 on Stromal cells scavenges CCL19 to enable CCR7-dependent trafficking of APCs from inflamed skin to lymph nodes. *J Immunol.* (2016) 196:3341–53. doi: 10.4049/jimmunol.1501542

16. Ulvmar MH, Werth K, Braun A, Kelay P, Hub E, Eller K, et al. The atypical chemokine receptor CCR11 shapes functional CCL21 gradients in lymph nodes. *Nat Immunol.* (2014) 15:623–30. doi: 10.1038/ni.2889

17. Comerford I, Nibbs RJ, Litchfield W, Bunting M, Harata-Lee Y, Haylock-Jacobs S, et al. The atypical chemokine receptor CCX-CKR scavenges homeostatic chemokines in circulation and tissues and suppresses Th17 responses. *Blood.* (2010) 116:4130–40. doi: 10.1182/blood-2010-06-34390

18. Lucas B, White AJ, Ulvmar MH, Nibbs RJ, Sitnik KM, Agace WW, et al. CCRL1/ACK4R is expressed in key thymic microenvironments but is dispensable for T lymphopoiesis at steady state in adult mice. *Eur J Immunol.* (2015) 45:574–83. doi: 10.1002/eji.201445015

19. Weber M, Hauschild R, Schwarz J, Mousson C, de Vries I, Legler DF, et al. Intestinal dendritic cell guidance by haptotactic chemokine gradients. *Science.* (2013) 339:328–32. doi: 10.1126/science.1228456

20. Bryce SA, Wilson RA, Tiplady EM, Asquith DL, Bromley SK, Luster AD, et al. ACKR4 on Stromal cells scavenges CCL19 to enable CCR7-dependent
galphai2 and galphai3 activation kinetics in single cells. *PLoS ONE.* (2016) 11:e0146789. doi: 10.1371/journal.pone.0146789

40. Otero C, Groettrup M, Legler DF. Opposite fate of endocytosed CC R7 and its ligands: recycling versus degradation. *J Immunol.* (2006) 177:2314–23. doi: 10.4049/jimmunol.177.4.2314

41. Hauser MA, Kindinger I, Laufer JM, Spate AK, Bucher D, Vanes SL, et al. Distinct CCR7 glycosylation pattern shapes receptor signaling and endocytosis to modulate chemotactic responses. *J Leukoc Biol.* (2016) 99:993–1007. doi: 10.1189/jlb.2VMA0915-432RR

42. Premont RT, Macrae AD, Stoffel RH, Chung N, Pitcher JA, Ambrose C, et al. Characterization of the G protein-coupled receptor kinase GRK4. Identification of four splice variants. *J Biol Chem.* (1996) 271:6403–10. doi: 10.1074/jbc.271.11.6403

43. Boehm JS, Zhao J, Yao J, Kim SY, Firestein R, Dunn IF, et al. Integrative genomic approaches identify IKKβ as a breast cancer oncogene. *Cell.* (2007) 129:1065–79. doi: 10.1016/j.cell.2007.03.052

44. Urizar E, Yano H, Kolster R, Gales C, Lambert N, Javitch JA. CODA-RET reveals functional selectivity as a result of GPCR heteromerization. *Nat Chem Biol.* (2011) 7:624–30. doi: 10.1038/nchembio.623

45. Moepps B, Tulone C, Kern C, Minisini R, Michels G, Vatter P, et al. Constitutive serum response factor activation by the viral chemokine receptor homologue pUS28 is differentially regulated by Galphai(11) and Galpha(16). *Cell Signal.* (2008) 20:1528–37. doi: 10.1016/j.cellsig.2008.04.010

46. Moepps B, Thelen M. Monitoring scavenging activity of chemokine receptors. *Meth Enzymol.* (2016) 570:539–65. doi: 10.1016/bs.mie.2015.11.003

47. Veldkamp CT, Koplinski CA, Jensen DR, Peterson FC, Smits KM, Smith BL, et al. Production of recombinant chemokines and validation of refolding. *Meth Enzymol.* (2016) 570:539–65. doi: 10.1016/bs.mie.2015.11.003

48. Laufer JM, Hauser MA, Kindinger I, Purvanov V, Pauli A, Legler DF. Chemokine receptor CCR7 triggers an endomembrane signaling complex for spatial rac activation. *Cell Rep.* (2019) 29:995–1009.e1006. doi: 10.1016/j.celrep.2019.09.031

49. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. *Nat Methods.* (2012) 9:676–82. doi: 10.1038/nmeth.2019

50. Rueden CT, Schindelin J, Hiner MC, DeZonia BE, Walter AE, Arena ET, et al. Imagej2: Imagej for the next generation of scientific image data. *BMC Bioinformatics.* (2017) 18:529. doi: 10.1186/s12859-017-1934-z

51. Thomsen AR, Plouffe B, Cahill TJ, III, Shukla AK, Tarrasch JT, Dosey AM, et al. GPCR-G Protein-beta-arrestin super-complex mediates sustained G protein signaling. *Cell.* (2016) 166:907–19. doi: 10.1016/j.cell.2016.07.004

52. Laufer JM, Kindinger I, Artinger M, Pauli A, Legler DF. CCR7 Is Recruited to the immunological synapse, acts as co-stimulatory molecule and drives LFA-1 clustering for efficient T cell adhesion through ZAP70. *Front Immunol.* (2019) 9:3115. doi: 10.3389/fimmu.2018.03115

53. Naumann U, Cameroni E, Pruenster M, Mahabaleshwar H, Raz E, Zerwes HG, et al. CXCR7 functions as a scavenger for CXCL12 and CXCL11. *PLoS ONE.* (2010) 5:e9175. doi: 10.1371/journal.pone.0009175

54. O’Hayre M, Eichel K, Avino S, Zhao X, Steffen DJ, Feng X, et al. Genetic evidence that beta-arrestins are dispensable for the initiation of beta2-adrenergic receptor signaling to ERK. *Sci Signal.* (2017) 10:eaal3395. doi: 10.1126/scisignal.aal3395

55. Sierro F, Biben C, Martinez-Munoz L, Mellado M, Ransohoff RM, Li M, et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. *Proc Natl Acad Sci USA.* (2007) 104:14759–64. doi: 10.1073/pnas.0702229104

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Matti, Salnikov, Artinger, D’Agostino, Kindinger, Ugoccioli, Thelen and Legler. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.